Kiniksa Pharmaceuticals International CAO Michael R. Megna Sells $1.11M of Stock
Michael R. Megna, CAO, sold 11,280 shares of Kiniksa Pharmaceuticals International, plc at $98.54 a share, worth $1.11M in total on Nov 9, 2026. Shares held after the trade: 12,697 (-47.0%).
Kiniksa Pharmaceuticals International Chairman & CEO Sanj K. Patel Sells $14.3M of Stock
Sanj K. Patel, Chairman & CEO, sold 151,300 shares of Kiniksa Pharmaceuticals International, plc at $92.35 to $96.05 a share (average $94.71) in 5 transactions, worth $14.3M in total on Nov 4, 2026. Shares held after the trade: 774,500 (-3.4%).
Kiniksa Pharmaceuticals International Chairman & CEO Sanj K. Patel Sells $37.4M of Stock
Sanj K. Patel, Chairman & CEO, sold 402,394 shares of Kiniksa Pharmaceuticals International, plc at $90.77 to $98.16 a share (average $92.92) in 14 transactions, worth $37.4M in total between Oct 30, 2026 and Nov 3, 2026. Shares held after the trade: 780,037 (-0.6%).
Kiniksa Pharmaceuticals International CFO Mark Ragosa Sells $3.39M of Stock
Mark Ragosa, CFO, sold 36,783 shares of Kiniksa Pharmaceuticals International, plc at $91.40 to $94.01 a share (average $92.16) in 4 transactions, worth $3.39M in total on Nov 2, 2026. Shares held after the trade: 20,854 (-1.0%).
Kiniksa Pharmaceuticals International CMO John F. Paolini Sells $8.94M of Stock
John F. Paolini, CMO, sold 96,000 shares of Kiniksa Pharmaceuticals International, plc at $92.02 to $97.77 a share (average $93.09) in 10 transactions, worth $8.94M in total between Oct 30, 2026 and Nov 2, 2026. Shares held after the trade: 69,922 (-1.0%).
Kiniksa Pharmaceuticals International COO Ross Moat Sells $9.63M of Stock
Ross Moat, COO, sold 103,585 shares of Kiniksa Pharmaceuticals International, plc at $91.23 to $97.76 a share (average $92.93) in 11 transactions, worth $9.63M in total between Oct 30, 2026 and Nov 2, 2026. Shares held after the trade: 10,294 (-6.6%).
Kiniksa Pharmaceuticals International CAO Michael R. Megna Sells $3.42M of Stock
Michael R. Megna, CAO, sold 36,260 shares of Kiniksa Pharmaceuticals International, plc at $91.87 to $97.74 a share (average $94.43) in 7 transactions, worth $3.42M in total on Oct 30, 2026. Shares held after the trade: 12,697 (-29.6%).
Kiniksa Pharmaceuticals reported total product revenue of $285.97 million for the third quarter of 2026, a significant increase from $180.86 million in the prior year. Net income for the quarter rose to $47.35 million, while the company maintained a strong liquidity position with $568.76 million in cash, cash equivalents, and short-term investments.
Kiniksa Pharmaceuticals International Financial Results
Kiniksa Pharmaceuticals reported Q3 2026 financial results, highlighted by ARCALYST net product revenue of $286.0 million, a 58% year-over-year increase. The company raised its full-year 2026 ARCALYST net product revenue guidance to a range of $1.045 billion to $1.050 billion.
“Kiniksa continues to build a leading IL-1α and IL-1β inhibition franchise, driven by the commercialization of ARCALYST in recurrent pericarditis. In the third quarter, strong commercial execution led to gains in patient and physician adoption, resulting in revenue of $286.0 million and positioning ARCALYST to achieve blockbuster status this year”
Sanj K. Patel, Chairman & Chief Executive Officer of Kiniksa
Kiniksa Pharmaceuticals International Executive Compensation
Kiniksa Pharmaceuticals appointed Ross Moat as President and Chief Operating Officer, effective immediately. The company also approved an increase in Moat's annual base salary to $700,000 and his annual target bonus to 60%, effective January 1, 2027.